Nacuity Pharmaceuticals is a clinical-stage leader in innovative treatments for oxidative stress. The company’s powerful, targeted therapies aim to stop oxidative tissue damage, a driver of blinding eye diseases and a broad spectrum of serious chronic conditions. Nacuity has highly differentiated clinical programs, including retinitis pigmentosa, cataract, and cystinosis. The company is pursuing near-term proof-of-concept data in all three programs.
Nacuity seeks to expand the science and clinical potential for prescription products addressing diseases and conditions involving oxidative stress. This largely unaddressed disease mechanism is potentially a key factor in maladies ranging from ophthalmic diseases and conditions, both rare and prevalent, to many serious non-ophthalmic diseases and conditions associated with aging, neurodegeneration and cellular dysfunction.
Based in Fort Worth, TX, Nacuity is founded by veterans of Alcon Laboratories experienced in research, development, and commercialization of products to address ophthalmic disease and conditions. The company’s core science is based on the extensive research of Dr. Peter Campochiaro of the Wilmer Eye Institute involving oxidative stress in the retina. Nacuity has key backing and technical support from Foundation Fighting Blindness and RD Fund, the world’s leading private funders of retinal disease research.
Mission & Vision
We aim to bring powerful, targeted treatments to underserved patient communities afflicted by blinding eye diseases and serious chronic conditions in which oxidative stress plays a role.
Leadership
Scientific Advisory Board
Business Advisory Board
Consultants
Joy Cavagnaro, Ph.D., DABT, ATS, RAC, FRAPS
President, Access BIO
- Areas of expertise include translation of novel therapeutic modalities: vaccines, cellular and gene therapies, animal-based and plant-based biotherapeutics, biotechnology-derived and tissue engineered products. Over 25 years of experience in biotech spanning academia, the CRO and biotech industries, and government (CBER/FDA)
- Serves as a SAB Member for several companies globally
- Education: Ph.D. in Biochemistry, UNC Chapel Hill; postgraduate work at Duke and Boston University Medical Centers
James R. Herman, Ph.D., DABT
President and Partner, INDS, Inc.; Consultant, Preclinical Science- Previously, Drug Safety Research Site Lead at Pfizer Global Research and Development in Ann Arbor, MI, responsible for all personnel, resources, policies and procedures in General Toxicology, Pathology, and Investigative Toxicology (including Clinical Pathology labs)
- Authored and/or critically reviewed nonclinical portions of over 100 IND and NDA submissions, including sections required for IBs and product labeling, and in addressing impurity issues
- Education: Ph.D., University of Wisconsin, Madison
Douglas G. Johnson, Ph.D.
President, OCAM Solutions, Inc.- Consultant, Chemistry and Manufacturing. Over 20 years of experience in the pharmaceutical industry
- Previously led chemistry and manufacturing for 10+ years at Allos Therapeutics where he was Vice President of Manufacturing and Vice President of Pharmaceutical Sciences
- Education: B.A. in Philosophy, Wheaton College; Ph.D., Organic Chemistry, University of Minnesota
Onkar Singh, Ph.D., MBA
Formulations Consultant, President, OS Pharma Consulting, LLC
- VP, Alentia Therapeutics (solid oral dosage-neurodegeneration)
- Previously: Director, Product Development, Henry M. Jackson Foundation for the Advancement of Military Medicine (HIV vaccine); Director, Pharm Dev at CONRAD (EVMS) (tablet, implants, patch, nanoparticles); Director, Insys Therapeutics (oral solution, sublingual, nasal sprays); Sr CMC Team Leader, 20-years at Alcon Labs/ Novartis (sterile otic, ophthalmic, nasal drug products)
- Education: B.Pharm, Pharmacy, & M. Pharm, Pharmaceutics, Indian Institute of Technology (IIT), Banaras Hindu University; PhD Pharmaceutics, Univ. of Illinois at Chicago; MBA, Univ. of Texas at Arlington
